Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels

Abstract 

Background

β-amyloid peptide (Aβ) is associated with neurodegeneration in Alzheimer’s disease. Emerging evidence indicates that Aβ levels in cerebrospinal fluid (CSF) may serve as an early clinical biomarker for evaluating pharmacological activity of new drug candidates targeting Aβ production or Aβ clearance. Therefore, it is critical to understand whether intrasubject levels of CSF Aβ are consistent between sampling intervals to determine whether Aβ can be used as a pharmacodynamic biomarker for drug candidates. Previous studies have produced seemingly conflicting observations for the intrasubject stability of CSF Aβ levels; we attempt to reconcile these conflicting observations.

Methods

The current study examined the Aβ levels in CSF collected with various sampling frequencies from three clinical studies conducted in healthy young or elderly subjects at the same investigative site for the purpose of designing future studies.

Results

The results suggest that CSF sampling frequency and/or sampling volume contributes to intrasubject variability in CSF Aβ levels, and that lowering the CSF sampling frequency may help minimize this effect.

Conclusion

These results will help guide clinical trial design for Alzheimer’s disease therapy.

Keywords: Alzheimer’s disease, Biomarker, Cerebrospinal fluid, Amyloid, Clinical trial